Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11939372 Binding agents

Patent 11939372 was granted and assigned to Amgen on March, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Amgen
Amgen
0
Date Filed
October 23, 2019
0
Date of Patent
March 26, 2024
0
Patent Applicant
Amgen
Amgen
0
Patent Application Number
16661669
0
Patent Citations
‌
US Patent 7592429 Sclerostin-binding antibody
0
‌
US Patent 7642238 Molecular determinants of myeloma bone disease and uses thereof
0
‌
US Patent 7758858 Antibodies associated with alterations in bone density
0
‌
US Patent 7868134 Immunogenic peptides derived from sclerostin
0
‌
US Patent 7872106 Sclerostin-binding antibodies
0
‌
US Patent 8017120 Method for inhibiting bone resorption
0
‌
US Patent 8178099 Methods of altering bone growth by administration of sost or wise antagonist or agonist
0
‌
US Patent 8329176 Method for inhibiting bone resorption
0
‌
US Patent 8715663 Epitopes
0
‌
US Patent 9133272 Bispecific binding agents
0
•••
Patent Inventor Names
Christopher J. Paszty
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11939372
0
Patent Primary Examiner
‌
Sharon X Wen
0

Find more entities like US Patent 11939372 Binding agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.